Literature DB >> 11747325

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma.

M Schmidinger1, C Wenzel, G J Locker, F Muehlbacher, R Steininger, M Gnant, R Crevenna, A C Budinsky.   

Abstract

We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m(2) PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxicities were moderate. In view of these encouraging findings, further studies appear warranted.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11747325      PMCID： PMC2364023          DOI： 10.1054/bjoc.2001.2149

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  25 in total

1.  Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.

Authors:  G Falkson; C G Moertel; P Lavin; F J Pretorius; P P Carbone
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

2.  A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge.

Authors:  Y Sasaki; S Imaoka; H Kasugai; M Fujita; S Kawamoto; S Ishiguro; J Kojima; O Ishikawa; H Ohigashi; H Furukawa
Journal:  Cancer       Date:  1987-09-15       Impact factor: 6.860

3.  Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.

Authors:  I Judson; J A Radford; M Harris; J Y Blay; Q van Hoesel; A le Cesne; A T van Oosterom; M J Clemons; C Kamby; C Hermans; J Whittaker; E Donato di Paola; J Verweij; S Nielsen
Journal:  Eur J Cancer       Date:  2001-05       Impact factor: 9.162

4.  Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report.

Authors:  T Konno; H Maeda; K Iwai; S Tashiro; S Maki; T Morinaga; M Mochinaga; T Hiraoka; I Yokoyama
Journal:  Eur J Cancer Clin Oncol       Date:  1983-08

5.  Hepatocellular carcinoma in Central Europe: prognostic features and survival.

Authors:  M Schöniger-Hekele; C Müller; M Kutilek; C Oesterreicher; P Ferenci; A Gangl
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

6.  Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study.

Authors:  R L Hong; Y L Tseng; F H Chang
Journal:  Ann Oncol       Date:  2000-03       Impact factor: 32.976

7.  Caelyx in malignant mesothelioma: a phase II EORTC study.

Authors:  P Baas; J van Meerbeeck; H Groen; H Schouwink; S Burgers; S Daamen; G Giaccone
Journal:  Ann Oncol       Date:  2000-06       Impact factor: 32.976

8.  Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.

Authors:  G Falkson; J M MacIntyre; A J Schutt; B Coetzer; L A Johnson; I W Simson; H O Douglass
Journal:  J Clin Oncol       Date:  1984-06       Impact factor: 44.544

9.  Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration.

Authors:  A Gabizon; A Meshorer; Y Barenholz
Journal:  J Natl Cancer Inst       Date:  1986-08       Impact factor: 13.506

10.  Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. With particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil.

Authors:  S Fujimoto; M Miyazaki; F Endoh; O Takahashi; K Okui; Y Morimoto
Journal:  Cancer       Date:  1985-11-15       Impact factor: 6.860
View more
  5 in total

1.  Treatment of hepatoma with liposome-encapsulated adriamycin administered into hepatic artery of rats.

Authors:  Dong-Sheng Sun; Jiang-Hao Chen; Rui Ling; Qing Yao; Ling Wang; Zhong Ma; Yu Li
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

2.  Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.

Authors:  Giuseppe Di Lorenzo; Antonio Rea; Chiara Carlomagno; Stefano Pepe; Giovannella Palmieri; Roberto Labianca; Antonio Chirianni; Alfonso De Stefano; Vincenzo Esposito; Sabino De Placido; Vincenzo Montesarchio
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 3.  Targeted pharmaceutical nanocarriers for cancer therapy and imaging.

Authors:  Vladimir P Torchilin
Journal:  AAPS J       Date:  2007-05-11       Impact factor: 4.009

Review 4.  Recent trends of polymer mediated liposomal gene delivery system.

Authors:  Shyamal Kumar Kundu; Ashish Ranjan Sharma; Sang-Soo Lee; Garima Sharma; C George Priya Doss; Shin Yagihara; Do-Young Kim; Ju-Suk Nam; Chiranjib Chakraborty
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

5.  Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study.

Authors:  J W Valle; A Dangoor; J Beech; D J Sherlock; S M Lee; J H Scarffe; R Swindell; M Ranson
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.